Journal article
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: A randomized controlled trial
MD Snape, KP Perrett, KJ Ford, TM John, D Pace, LM Yu, JM Langley, S McNeil, PM Dull, F Ceddia, A Anemona, SA Halperin, S Dobson, AJ Pollard
JAMA | AMER MEDICAL ASSOC | Published : 2008
Abstract
Context: Immunization with a meningococcal tetravalent (serogroup ACWY) glycoconjugate vaccine is recommended for all US adolescents. However, the currently licensed vaccine is poorly immunogenic in infancy, when the highest rates of disease are observed. Objective: To determine the immunogenicity of a novel tetravalent CRM197-conjugated meningococcal vaccine (MenACWY) in infants. Design, Setting, and Participants: Randomized, open-label, controlled study of 225 UK and 196 Canadian 2-month-olds from August 2004 to September 2006. Intervention: UK infants received a primary course of MenACWY (at 2, 3, and 4 months or 2 and 4 months) or Neisseria meningitidis serogroup C monovalent meningococc..
View full abstract